Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9QQQ

Cryo-EM structure of SKM-70S ribosomal stalled complex in the major state (vacant A-site, canon)

This is a non-PDB format compatible entry.
Summary for 9QQQ
Entry DOI10.2210/pdb9qqq/pdb
Related9QSJ 9SRO
EMDB information53311
DescriptorSmall ribosomal subunit protein bS1, Small ribosomal subunit protein uS4, Small ribosomal subunit protein uS5, ... (59 entities in total)
Functional Keywordsantibiotics, 70s complex, body closure, accomodation, ribosome
Biological sourceEscherichia coli B
More
Total number of polymer chains55
Total formula weight2266257.19
Authors
Morici, M.,Corazza, M.,Safdari, H.A.,Wilson, D.N. (deposition date: 2025-04-01, release date: 2026-02-18)
Primary citationWright, G.,Cook, M.,Xu, M.,Morici, M.,Travin, D.,Wang, W.,Klepacki, D.,Chhabra, N.,Rao, V.,Sahile, H.,Hackenberger, D.,Safdari, H.,Berger, M.,Corazza, M.,Bond, A.,Guitor, A.,Tertigas, D.,Wang, L.,Schaenzer, A.,Ejim, L.,Yarlagadda, V.,Gomez, J.,Surette, M.,Av-Gay, Y.,Dhar, N.,Hung, D.,Vazquez-Laslop, N.,Mankin, A.,Wilson, D.
Saskemycin, a potent and selective antimycobacterial agent targeting a unique site on the ribosome.
Res Sq, 2025
Cited by
PubMed Abstract: Tuberculosis is the deadliest bacterial disease on the planet. The months-long regimen of multiple antibiotics required to treat tuberculosis profoundly affects the microbiome and leads to the development of antimicrobial resistance. Furthermore, non-tuberculous mycobacterial infections pose an increasing clinical challenge. Consequently, there is a growing need for new narrow-spectrum mycobacteria-targeting antibiotics with different mechanisms of action. Here, we report the discovery and characterization of a natural glycolipid antibiotic, saskemycin (SKM), which demonstrates potent and highly selective activity against mycobacteria. Genome sequencing, chemical analysis, and isotope feeding strategies reveal the unique structure and biosynthetic origin of SKM. SKM binds to the small ribosomal subunit at a site not targeted by any of the clinically relevant antibiotics acting on the ribosome. Bound to the ribosome, SKM corrupts the decoding center in a unique way, preventing stable binding of aminoacyl-tRNA in the A site and inhibiting translation in a sequence context-specific manner. Self-resistance in the producing organism is conferred by methylation of a single 16S rRNA nucleotide by SasO and SasN rRNA methyltransferases. These enzymes are orthologs of the ubiquitous RsmC and SpoU methyltransferases found in most bacterial genera but absent in mycobacteria, rationalizing SKM's exquisite selectivity. The discovery of SKM provides an entry point for the development of selective, microbiome-sparing antimycobacterial antibiotics with a unique structure, binding site, and mechanism of action.
PubMed: 41282059
DOI: 10.21203/rs.3.rs-7820265/v1
PDB entries with the same primary citation
Experimental method
ELECTRON MICROSCOPY (2.26 Å)
Structure validation

249697

PDB entries from 2026-02-25

PDB statisticsPDBj update infoContact PDBjnumon